NASDAQ:ERNA Ernexa Therapeutics Earnings Date & Estimates $2.40 -0.09 (-3.61%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.35 -0.05 (-2.25%) As of 10/9/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ernexa Therapeutics is expected to report earnings on Friday, November 6, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 6, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Ernexa TherapeuticsErnexa Therapeutics is expected to post earnings of -$3.84 per share. In the same quarter a year earlier Ernexa Therapeutics reported -$3.75 per share. Ernexa Therapeutics last reported on August 6, 2026, posting -$3.40 per share and missing the -$3.30 consensus estimate.Consensus EstimatesConsensus EPS-$3.84Prior-Year EPS-$3.75Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$3.40 (Missed by -$0.10)Prepare for the Earnings CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Ernexa Therapeutics Earnings FAQ When does Ernexa Therapeutics report earnings? Ernexa Therapeutics (NASDAQ:ERNA) is estimated to report earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Ernexa Therapeutics? Analysts expect Ernexa Therapeutics to post earnings of -$3.84 per share for the quarter. Ernexa Therapeutics Earnings HeadlinesAutolus Therapeutics (NASDAQ:AUTL) vs. Ernexa Therapeutics (NASDAQ:ERNA) Financial ComparisonOctober 8 at 4:59 AM | americanbankingnews.comErnexa Therapeutics Announces ERNA-101 Preclinical Data Selected For Flash Talk Presentation At Nature Conferences? Next-Generation Cancer Therapeutics Meeting Co-Hosted By MD ...October 7, 2026 | marketscreener.comMTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)Relay Therapeutics (NASDAQ:RLAY) and Ernexa Therapeutics (NASDAQ:ERNA) Head-To-Head AnalysisOctober 7, 2026 | americanbankingnews.comErnexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterOctober 6, 2026 | finance.yahoo.comErnexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterOctober 6, 2026 | globenewswire.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
